Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria

被引:67
作者
Uneke, CJ
Ogbu, O
Inyama, PU
Anyanwu, GI
Njoku, MO
Idoko, JH
机构
[1] Ebonyi State Univ, Dept Med Microbiol, Fac Clin Med, Coll Hlth Sci, Abakaliki, Nigeria
[2] Univ Jos, AIDS Leishmaniasis Res Lab, Dept Zool, Jos, Nigeria
[3] GEDE AIDS & Infect Dis Res Inst, Maitama Abuja, Nigeria
[4] Univ Jos, Teaching Hosp, Dept Med Microbiol, Jos, Nigeria
来源
MEMORIAS DO INSTITUTO OSWALDO CRUZ | 2005年 / 100卷 / 01期
关键词
hepatitis B virus; human immunodeficiency virus; blood donor; prevalence;
D O I
10.1590/S0074-02762005000100002
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Information is very scarce on the prevalence of hepatitis-B virus (HBV) infection among blood donors and patients with human immunodeficiency virus (HIV) infection in Nigeria. Hepatitis-B surface antigen (HBsAg) ELISA was used to determined the prevalence of HBsAg among 175 blood donors (aged 20-40 years) and 490 HIV-infected patients (aged 17 - 60 years) in Jos, Nigeria. Twenty-five (14.3%) of the blood donors and 127 (25.9%) of the HIV-infected individuals were HBsAg seropositive, indicating a higher HBV infection among HIV-infected persons than among healthy blood donors. A slightly higher HBsAg seroprevalence was recorded in the males (14.6%) than females (12.9%) of the blood donors. Among the HIV-infected patients, the males had considerably higher HBsAg seroprevalence than the females (31.8 vs 22.1%) with the highest prevalence of HBsAg occurring in the 51-60 years age group (44%), followed by those of 31-40 years (28.2%). Results confirmed the high endemicity of HBV infection in Jos, Nigeria and the significantly greater prevalence of HBV infection among HIV-infected patients than among blood donors.
引用
收藏
页码:13 / 16
页数:4
相关论文
共 13 条
[1]  
DIENSTAG JL, 1998, HARRISONS PRINCIPLES, V1, P1696
[2]   Prevalence of hepatitis B virus DNA in anti-HBc-positive/HBsAg-negative sera correlates with HCV but not HIV serostatus [J].
Drosten, C ;
Nippraschk, T ;
Manegold, C ;
Meisel, H ;
Brixner, V ;
Roth, WK ;
Apedjinou, A ;
Günther, S .
JOURNAL OF CLINICAL VIROLOGY, 2004, 29 (01) :59-68
[3]  
Ekpo M, 1995, NIGERIAN MED J, V29, P35
[4]  
FAUCI AS, 1998, HARRISONS PRINCIPLES, V1, P718
[5]  
Federal Ministry of Health Nigeria, 2003, NAT HIV AIDS REPR HL
[6]  
Finlayson MDC, 1999, DAVIDSONS PRINCIPLES, P706
[7]  
Hodgson D, 1998, Urol Oncol, V4, P3, DOI 10.1016/S1078-1439(98)00025-8
[8]  
OSMOND DH, 1994, AIDS KNOWLEDGE BASE
[9]  
Sirisena N D, 2002, Niger Postgrad Med J, V9, P7
[10]  
TREITINGER A, 2004, BRAZ J INFECT DIS, V4, P192